Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574172 | 0.83 | ALDH1A1 (0.46) | ALDH1A1LMNANFE2L2 | |
| SCHEMBL29525702 | 0.77 | ERN1 (0.47) | ALDH1A1LMNAGAAMAPTSMN1; SMN2 | |
| SCHEMBL16954945 | 0.77 | MAPT (0.41) | ALDH1A1LMNAGAAMAPTSMN1; SMN2 | |
| SCHEMBL223145 | 0.77 | ERN1 (0.47) | ALDH1A1LMNAGAAMAPTSMN1; SMN2 | |
| SCHEMBL30037631 | 0.77 | ERN1 (0.47) | ALDH1A1LMNAGAAMAPTSMN1; SMN2 | |
| SCHEMBL6873694 | 0.77 | LMNA (0.38) | LMNAGAAMAPTSMN1; SMN2HSD11B1 | |
| SCHEMBL466535 | 0.76 | NFE2L2 (0.44) | ALDH1A1NFE2L2 | |
| SCHEMBL180459 | 0.76 | ALDH1A1 (0.41) | ALDH1A1HSD11B1 | |
| SCHEMBL29620247 | 0.76 | NFE2L2 (0.44) | ALDH1A1NFE2L2 | |
| SCHEMBL29661897 | 0.76 | ALDH1A1 (0.41) | ALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| WO-2020112937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2017158151-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-09-21 | — | — | WO | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-8076367-B2 | Benzimidazolylidene propane-1,3-dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20100173946-A1 | BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7709519-B2 | Benzimidazolylidene propane-1,3 dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20090018177-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1752452-A9 | PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1752452-A1 | PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-02-14 | — | — | EP | disclosed |
| CN-1342149-A | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | ABBOTT LAB (US) | 2002-03-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885LMNA 2078/4885GAA 1899/4885 |
| US-20090018177-A1 | Propane-1,3-Dione Derivative or Salt Thereof | GPER1, GNRHR, AR | ALDH1A1 719/4885LMNA 1918/4885GAA 4076/4885 |
| US-20100173946-A1 | BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF | GPER1, GNRHR, AR | ALDH1A1 1046/4885LMNA 2490/4885GAA 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.